21:43 , Oct 27, 2017 |  BC Week In Review  |  Company News

Astellas partners with TB Alliance to develop new TB drugs

Astellas Pharma Inc. (Tokyo:4503) partnered with non-profit organization Global Alliance for TB Drug Development to identify new drugs to treat tuberculosis (TB). Astellas will provide its original compound library, which TB Alliance will screen for...
00:06 , Aug 5, 2017 |  BioCentury  |  Regulation

Enabling efficiency in TB

In combination with adaptive study designs, a real-time biomarker of treatment response that is making its way toward FDA could shave years off the development of tuberculosis regimens, according to multiple stakeholders who attended a...
21:45 , Dec 7, 2016 |  BC Innovations  |  Strategy

The Sharing Economy

Arguably the biggest indicator that pharmas have shed the isolationist, know-it-all attitudes that drove their strategies for decades is the growth of compound-sharing initiatives to spur drug discovery. A handful of companies is leading the...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Company News

Kenya Ministry of Health, TB Alliance sales and marketing update

The Kenya Ministry of Health, TB Alliance and other partners launched in Kenya the first child-friendly formulation of tuberculosis drugs. TB Alliance said the pills are flavored and dissolve in water. Kenya Ministry of Health,...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Company News

Takeda, TB Alliance deal

TB Alliance and Takeda partnered to develop compounds to treat tuberculosis. The compounds were generated from a high throughput screening program using Takeda’s library of 20,000 compounds under a 2013 deal between TB Alliance and...
01:17 , Apr 21, 2016 |  BC Extra  |  Politics & Policy

TB Alliance partners with Medicines Patent Pool

The Global Alliance for TB Drug Development and the Medicines Patent Pool (MPP) will collaborate to share IP and form licensing strategies for future tuberculosis treatments developed by the TB Alliance. The partners aim to...
07:00 , Oct 19, 2015 |  BioCentury  |  Regulation

Unleashing China's innovators

An ambitious slate of reforms proposed by China's State Council could at last relieve the regulatory bottlenecks that have long hobbled development of innovative drugs in and for China by domestic and multinational pharmas alike. ...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Company News

Critical Path Institute, TB Alliance, St. George’s University, WHO infectious news

WHO’s Special Program for Research and Training in Tropical Diseases (TDR), TB Alliance and St. George’s University selected Critical Path to host and curate a new tuberculosis (TB) clinical trial data sharing program containing results...
07:00 , Jun 4, 2015 |  BC Innovations  |  Tools & Techniques

Spit decision

A new method for sequencing whole bacterial genomes from sputum, developed by a group at University College London, could cut the time it takes to diagnose tuberculosis from weeks to days by eliminating the need...
07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

PA-824: Phase III started

Not-for-profit TB Alliance began the open-label, South African Phase III Nix-TB trial to evaluate the all-oral regimen of PA-824, Sirturo bedaquiline and Zyvox linezolid in about 200 patients ages >=14. Patients will receive...